Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey

We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharm...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Pierre-André Jarrot, Adrien Mirouse, Sébastien Ottaviani, Simon Cadiou, Jean-Hugues Salmon, Eric Liozon, Simon Parreau, Martin Michaud, Benjamin Terrier, Pierre-Edouard Gavand, Ludovic Trefond, Virginie Lavoiepierre, Jeremy Keraen, Daniel Rekassa, Bastien Bouldoires, Thierry Weitten, Damien Roche, Antoine Poulet, Caroline Charpin, Vincent Grobost, Marion Hermet, Magali Pallure, Chloe Wackenheim, Ludovic Karkowski, Pierre Grumet, Thomas Rogier, Nabil Belkefi, Vincent Pestre, Emilie Broquet, Amélie Leurs, Sophie Gautier, Valérie Gras, Pierre Gilet, Jan Holubar, Nadia Sivova, Nicolas Schleinitz, Jean-Marc Durand, Brice Castel, Alexandre Petrier, Robin Arcani, Baptiste Gramont, Philippe Guilpain, Hubert Lepidi, Pierre-Jean Weiller, Joelle Micallef, David Saadoun, Gilles Kaplanski
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2024-12-01
coleção:	Human Vaccines & Immunotherapeutics
Assuntos:	Polymyalgia rheumatica giant cell arteritis COVID-19 vaccination pharmacovigilance clinical study
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2334084
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!